Related references
Note: Only part of the references are listed.Modulation of immune cell reactivity with cis-binding Siglec agonists
Corleone S. Delaveris et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
The Roles of Siglec7 and Siglec9 on Natural Killer Cells in Virus Infection and Tumour Progression
Yayun Zheng et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2020)
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Raju K. Vaddepally et al.
CANCERS (2020)
Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis
Evan S. Dellon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells
Silke Eisinger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Current Status on Therapeutic Molecules Targeting Siglec Receptors
Maria Pia Lenza et al.
CELLS (2020)
Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets
Luca Cassetta et al.
CANCER CELL (2019)
Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
Jun Wang et al.
NATURE MEDICINE (2019)
Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment
Quentin Haas et al.
CANCER IMMUNOLOGY RESEARCH (2019)
CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
Amira A. Barkal et al.
NATURE (2019)
The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice
Dannielle D. Engle et al.
SCIENCE (2019)
Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways
Polina Weitzenfeld et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell-Mediated Tumor Immunity
Christian Bull et al.
CANCER RESEARCH (2018)
Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells
Michal A. Stanczak et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Resistance to PD1/PDL1 checkpoint inhibition
Jake S. O'Donnell et al.
CANCER TREATMENT REVIEWS (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Sialic acids in cancer biology and immunity
Oliver M. T. Pearce et al.
GLYCOBIOLOGY (2016)
The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9
Richard Beatson et al.
NATURE IMMUNOLOGY (2016)
Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis
Anna-Maria Georgoudaki et al.
CELL REPORTS (2016)
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis (vol 28, pg 285, 2015)
Rony Dahan et al.
CANCER CELL (2015)
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
Sonja Kleffel et al.
CELL (2015)
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis
Seth B. Coffelt et al.
NATURE (2015)
Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model
Shihao Chen et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Lectin Galactoside-binding Soluble 3 Binding Protein (LGALS3BP) Is a Tumor-associated Immunomodulatory Ligand for CD33-related Siglecs
Heinz Laeubli et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance
Camilla Jandus et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion
Jason E. Hudak et al.
NATURE CHEMICAL BIOLOGY (2014)
Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer
Heinz Laubli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Siglec-mediated regulation of immune cell function in disease
Matthew S. Macauley et al.
NATURE REVIEWS IMMUNOLOGY (2014)
Siglecs as sensors of self in innate and adaptive immune responses
James C. Paulson et al.
GLYCOBIOLOGY OF THE IMMUNE RESPONSE (2012)
Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer
Minu K. Srivastava et al.
PLOS ONE (2012)
Tumor Entrained Neutrophils Inhibit Seeding in the Premetastatic Lung
Zvi Granot et al.
CANCER CELL (2011)
Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies
Fubin Li et al.
SCIENCE (2011)
Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy
David G. DeNardo et al.
CANCER DISCOVERY (2011)
Immunomodulation of monocyte-derived dendrite cells through ligation of tumor-produced mucins to Siglec-9
Mariko Ohta et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Comparative genomics indicates the mammalian CD33rSiglec locus evolved by an ancient large-scale inverse duplication and suggests all Siglecs share a common ancestral region
Huan Cao et al.
IMMUNOGENETICS (2009)
Siglecs and their roles in the immune system
Paul R. Crocker et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Divergent immunoglobulin G subclass activity through selective Fc receptor binding
F Nimmerjahn et al.
SCIENCE (2005)
Siglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the proinflammatory cytokine environment
S von Gunten et al.
BLOOD (2005)
FcγRIV:: A novel FcR with distinct IgG subclass specificity
F Nimmerjahn et al.
IMMUNITY (2005)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
